Kerala HC Stays Coercive Action Under New Digital Media Guidelines

Chennai : The Kerala High Court, on Wednesday, granted a stay on the operation of Part III of the Information Technology (Intermediary Guidelines and Digital Media Ethics Code) Rules, 2021 (the “Intermediary Rules 2021”) to LiveLaw Media Pvt. Ltd, in response to a writ petition filed by the legal news website.

LiveLaw’s petition was filed on March 9, 2021, and came up for hearing on Wednesday (March 10). LiveLaw’s arguments were centred on the fact that the parent statute, the IT Act, 2000, under which the Intermediary Rules 2021 have been purported to be made, don’t allow the regulation of digital news media.

The IT act applies to intermediaries. Hence, digital news media portals don’t fall under the ambit of the act. However, the new rules seek to regulate the content on news portals as well as video-streaming or OTT platforms by mandating a three-tier oversight mechanism.

At the first level, any person could write a complaint to a news website’s grievance officer about a particular piece of content on the website. The grievance officer would have to acknowledge the receipt of the complaint within 24 hours and communicate his/her decision to the complainant within 15 days. If the news website chooses to not remove the piece of content, then a self-regulating body appointed subject to the central government’s approval will judge the suitability of such content, and on the third level, the central government itself shall decide whether to remove such content.

The petitioner (LiveLaw) claimed that these rules have been framed despite the government not enjoying such powers to regulate news media under the IT Act.

On March 9, the Foundation for Independent Journalism (FIJ), which runs the news website The Wire (thewire.in), along with the editor of The News Minute (thenewsminute.com), also challenged the new guidelines in a writ petition filed in the Delhi High Court. While LiveLaw’s petition challenged all aspects of the new rules, including those applying to social media and OTT platforms, FIJ’s petition only challenged the section of the rules, specifically Part III, which applies to digital news media.

The Delhi HC has issued a notice on the matter, giving the Union of Indian time to file a counter-affidavit. The next hearing on the matter in the Delhi HC will be held on April 16, 2021.

  • Related Posts

    National Pharmaceutical Pricing Authority notifies retail price of 42 new drugs

    New Delhi:  The National Pharmaceutical Pricing Authority (NPPA) has notified retail price of 42 new drugs under the provisions of the Drugs Prices Control Order (DPCO), 2013, including anti hypertensive,…

    World’s First Malaria Treatment for Newborns and Young Infants Receives WHO Prequalification

    New Delhi– In a landmark development for global child health, the World Health Organization (WHO) has granted prequalification to Coartem® Baby (artemether-lumefantrine), the first and only antimalarial medicine specifically developed…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    A SSi Mantra fame Robotic Telesurgery Champion pulls off another Spectacular Intercontinental

    A SSi Mantra fame Robotic Telesurgery Champion pulls off another Spectacular Intercontinental

    National Pharmaceutical Pricing Authority notifies retail price of 42 new drugs

    National Pharmaceutical Pricing Authority notifies retail price of 42 new drugs

    World’s First Malaria Treatment for Newborns and Young Infants Receives WHO Prequalification

    World’s First Malaria Treatment for Newborns and Young Infants Receives WHO Prequalification

    FIR Lodged Against Pharmacist in Chandauli for Working Nearly 10 Years on Forged Documents

    FIR Lodged Against Pharmacist in Chandauli for Working Nearly 10 Years on Forged Documents

    Laughing all the Way to Health with Sir Ganga Ram Hospital

    Laughing all the Way to Health with Sir Ganga Ram Hospital

    Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

    Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson